Kidney cancer, version 2.2014.

These NCCN Guidelines Insights highlight treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma included in the 2014 version of the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer.

[1]  J. Manola,et al.  ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Robert J. Jones,et al.  Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma , 2013, BMC Urology.

[3]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[4]  R. Shah,et al.  Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship , 2012, The American journal of surgical pathology.

[5]  J. Ahn,et al.  Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[7]  V. Reuter,et al.  Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma , 2012, Investigational New Drugs.

[8]  J. Dutcher,et al.  Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy , 2011, Medical oncology.

[9]  C. Bokemeyer,et al.  Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  T. Choueiri,et al.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. , 2011, Hematology/oncology clinics of North America.

[11]  T. Olencki,et al.  Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Christmas,et al.  Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Jonasch,et al.  Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Choueiri,et al.  Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.

[15]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[16]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[18]  B. Delahunt,et al.  Uncommon and recently described renal carcinomas , 2009, Modern Pathology.

[19]  R. Figlin,et al.  Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.

[20]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[21]  P. Thall,et al.  A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. , 2008, The Journal of urology.

[22]  G. Sonpavde,et al.  Axitinib for renal cell carcinoma , 2008, Expert opinion on investigational drugs.

[23]  R. Ghavamian,et al.  Renal medullary carcinoma: the Bronx experience. , 2007, Urology.

[24]  A. Billis,et al.  Renal medullary carcinoma: report of seven cases from Brazil , 2007, Modern Pathology.

[25]  M. Guba,et al.  Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis , 2007, Cancer and Metastasis Reviews.

[26]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[27]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[28]  N. Rioux-Leclercq,et al.  Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.

[29]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[30]  S. Naito,et al.  Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.

[31]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[32]  N. Rioux-Leclercq,et al.  Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience , 2005 .

[33]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[34]  E. Small,et al.  A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Cheville,et al.  Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome , 2004, The American journal of surgical pathology.

[36]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[37]  V. Sukhatme,et al.  Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.

[38]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[40]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[41]  W. Linehan,et al.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. , 2012, The oncologist.

[42]  A. Ravaud,et al.  Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Picken,et al.  Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. , 2007, American journal of clinical pathology.

[44]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.